Edition:
United States

Mayne Pharma Group Ltd (MYX.AX)

MYX.AX on Australia Stock Exchange

0.77AUD
23 Feb 2018
Change (% chg)

$0.08 (+10.71%)
Prev Close
$0.70
Open
$0.67
Day's High
$0.78
Day's Low
$0.66
Volume
31,291,990
Avg. Vol
6,950,853
52-wk High
$1.59
52-wk Low
$0.59

Chart for

About

Mayne Pharma Group Limited is a specialty pharmaceutical company, which focuses on applying its drug delivery capability to commercialize branded and generic pharmaceuticals. The Company also provides contract development and manufacturing services. It operates in four segments: Generic Products (GPD), Specialty Brands (SBD),... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $1,079.19
Shares Outstanding(Mil.): 1,541.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.98 16.31
EPS (TTM): -- -- --
ROI: -- 14.12 35.74
ROE: -- 15.72 17.71

BRIEF-Mayne Pharma Group Posts H1 Loss Attributable Of $174.2 Mln

* ‍HY REVENUE FROM ORDINARY ACTIVITIES $243.3 MILLION VERSUS $294.8 MILLION

Feb 22 2018

BRIEF-Mayne Pharma adds two products to its Australian portfolio

* Mayne Pharma received TGA approval for Monurol (fosfomycin trometamol) (3g) granules and launched Urorec (silodosin) (8mg) capsules in Australia Source text for Eikon: Further company coverage:

Sep 14 2017

BRIEF-Mayne Pharma posts FY profit attributable of $88.6 mln

* FY revenue from ordinary activities up 114% to $572.6 million

Aug 24 2017

Earnings vs. Estimates